MUC4 Potentiates Invasion and Metastasis of Pancreatic Cancer Cells Through Stabilization of Fibroblast Growth Factor Receptor 1

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2012 Jul 14

PMID 22791819

Citations 51

Authors

Satyanarayana Rachagani

Muzafar A Macha

Moorthy P Ponnusamy

Dhanya Haridas

Sukhwinder Kaur

Maneesh Jain

Surinder K Batra

Affiliations

Soon will be listed here.

Abstract

MUC4 is a type-1 transmembrane mucin differentially expressed in multiple cancers and has previously been shown to potentiate progression and metastasis of pancreatic cancer. In this study, we investigated the molecular mechanisms associated with the MUC4-induced invasion and metastasis in pancreatic cancer. Stable silencing of MUC4 in multiple pancreatic cancer cells resulted in the downregulation of N-cadherin and its interacting partner fibroblast growth factor receptor 1 (FGFR1) through downregulation of partly by pFAK, pMKK7, pJNK and pc-Jun pathway and partly through PI-3K/Akt pathway. The downregulation of FGFR1 in turn led to downregulation of pAkt, pERK1/2, pNF-κB, pIkBα, uPA, MMP-9, vimentin, N-cadherin, Twist, Slug and Zeb1 and upregulation of E-cadherin, Occludin, Cytokeratin-18 and Caspase-9 in MUC4 knockdown BXPC3 and Capan1 cells compared with scramble vector transfected cells. Further, downregulation of FGFR1 was associated with a significant change in morphology and reorganization of the actin-cytoskeleton, leading to a significant decrease in motility (P < 0.00001) and invasion (P < 0.0001) in vitro and decreased tumorigenicity and incidence of metastasis in vivo upon orthotopic implantation in the athymic mice. Taken together, the results of the present study suggest that MUC4 promotes invasion and metastasis by FGFR1 stabilization through the N-cadherin upregulation.

Citing Articles

A new insight on alleviating the inhibitory effect of aflatoxin B1 on muscle development in grass carp (): The effect of 4-Methylesculetin in vivo and in vitro.

He X, Zhang J, Jiang W, Wu P, Liu Y, Ren H Anim Nutr. 2024; 19:339-354.

PMID: 39640553 PMC: 11617288. DOI: 10.1016/j.aninu.2024.08.001.

Using microRNAs Networks to Understand Pancreatic Cancer-A Literature Review.

Przybyszewski O, Mik M, Nowicki M, Kusinski M, Mikolajczyk-Solinska M, Sliwinska A Biomedicines. 2024; 12(8).

PMID: 39200178 PMC: 11351910. DOI: 10.3390/biomedicines12081713.

Surface plasmon resonance microscopy identifies glycan heterogeneity in pancreatic cancer cells that influences mucin-4 binding interactions.

Aguilar Diaz de Leon J, Thirumurty M, Ly N PLoS One. 2024; 19(5):e0304154.

PMID: 38776309 PMC: 11111020. DOI: 10.1371/journal.pone.0304154.

Protein interaction networks characterizing the A549 cells Klotho transfected are associated with activated pro-apoptotic Bim and suppressed Wnt/β-catenin signaling pathway.

Matsumoto M, Ogawa N, Fukuda T, Bando Y, Nishimura T, Usuda J Sci Rep. 2024; 14(1):2130.

PMID: 38267588 PMC: 10808115. DOI: 10.1038/s41598-024-52616-0.

Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN Initiation.

Hu C, Huang C, Hsu M, Chien H, Wu P, Chen Y Adv Sci (Weinh). 2023; 10(36):e2301240.

PMID: 37964407 PMC: 10754145. DOI: 10.1002/advs.202301240.

References

Liu Z, Neiss N, Zhou S, Henne-Bruns D, Korc M, Bachem M . Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res. 2007; 67(6):2712-9. DOI: 10.1158/0008-5472.CAN-06-3843. View

Ponnusamy M, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P . MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010; 29(42):5741-54. PMC: 3005772. DOI: 10.1038/onc.2010.309. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Swartz M, Batra S, Varshney G, Hollingsworth M, Yeo C, Cameron J . MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002; 117(5):791-6. DOI: 10.1309/7Y7N-M1WM-R0YK-M2VA. View

Gravdal K, Halvorsen O, Haukaas S, Akslen L . A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007; 13(23):7003-11. DOI: 10.1158/1078-0432.CCR-07-1263. View

Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S . Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004; 28(3):219-30. DOI: 10.1097/00006676-200404000-00002. View

Cavallaro U, Niedermeyer J, Fuxa M, Christofori G . N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol. 2001; 3(7):650-7. DOI: 10.1038/35083041. View

Rachagani S, Senapati S, Chakraborty S, Ponnusamy M, Kumar S, Smith L . Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer. 2011; 104(6):1038-48. PMC: 3065271. DOI: 10.1038/bjc.2011.31. View

10.

Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C . Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008; 8:82. PMC: 2292732. DOI: 10.1186/1471-2407-8-82. View

11.

Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J . MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2006; 55(2):195-203. DOI: 10.1016/j.lungcan.2006.10.013. View

12.

Chauhan S, Singh A, Ruiz F, Johansson S, Jain M, Smith L . Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol. 2006; 19(10):1386-94. DOI: 10.1038/modpathol.3800646. View

13.

Kalluri R . EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009; 119(6):1417-9. PMC: 2689122. DOI: 10.1172/JCI39675. View

14.

Moniaux N, Varshney G, Chauhan S, Copin M, Jain M, Wittel U . Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004; 52(2):253-61. DOI: 10.1177/002215540405200213. View

15.

Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E . Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10):1295-304. DOI: 10.1038/modpathol.3800445. View

16.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

17.

Peluso J . N-cadherin-mediated cell contact regulates ovarian surface epithelial cell survival. Biol Signals Recept. 2000; 9(2):115-21. DOI: 10.1159/000014630. View

18.

Mehlen P, Puisieux A . Metastasis: a question of life or death. Nat Rev Cancer. 2006; 6(6):449-58. DOI: 10.1038/nrc1886. View

19.

Moniaux N, Chaturvedi P, Varshney G, Meza J, Rodriguez-Sierra J, Aubert J . Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer. 2007; 97(3):345-57. PMC: 2360313. DOI: 10.1038/sj.bjc.6603868. View

20.

Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghaneh P . Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008; 99(1):6-13. PMC: 2453014. DOI: 10.1038/sj.bjc.6604436. View